RxDoctor Payments Data

Kul Aggarwal, MD

Interventional Cardiology · Columbia, MONPI 1720038300

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,560 of the $4,092 with a category attached, or 62.6%. 13 manufacturers reported payments, led by Abbott at 54.9% of the total. Reporting peaked in 2019 at $2,734 and has fallen 93.8% since, to $169 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MO, where the typical reported total is $10,448.

$4,092in general payments, 2019–2025

Across 62 payments — averaging $66.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$224
  • Boston Scientific$183
  • Biotronik Inc.$134
  • Siemens Medical Solutions USA, Inc.$37
  • plus $186 from 7 others
$519,402in research payments, 2019–2025

Across 15 payments — averaging $34,627 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$457K
  • AstraZeneca$24K
  • Amgen$22K
  • Merck$17K

What the payments were for

  • Travel & lodging$1,53237%
  • Food & beverage$2,56063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,092 in reported general payments places this provider in the 25th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$25,461
Medicare patients
1,240
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional cardiology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →